All In Biotech

Drug Trial Radar · NCT05531565

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Sep 13, 2022

Primary completion

Oct 20, 2026

Study completion Dec 14, 2027

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Sep 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that made it hard to continue. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the skin disease. Researchers will measure symptoms and signs of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI). The main questions researchers want to answer are: * How many participants have a score of 0 or 1 on the CLA-IGA-R looking at skin redness after treatment? * How many participants have their skin disease activity go down by at least 70% as measured by CLASI? Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and CLE have on the quality of life of participants using a group of questionnaires. The study will be split into 2 parts - Part A and Part B. Both parts will be done as follows: * After screening, participants will be randomized to receive either litifilimab or placebo for the 1st treatment period. A placebo looks like the study drug but contains no real medicine. * Participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. * The 1st treatment period will be double blinded which means neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * This double blinded treatment period will last 24 weeks, after which the 2nd treatment period will begin. * During the 2nd treatment period, all participants will receive litifilimab for 28 weeks. * After completing treatment in this study, participants that qualify will be given the choice to join the Long-Term Extension study, 230LE305. If they do not, they will move into a follow-up safety period that will last up to 24 weeks. * The total study duration for participants will be up to 80 weeks.

Conditions

  • Subacute Cutaneous Lupus Erythematosus
  • Chronic Cutaneous Lupus Erythematosus

Interventions

  • LitifilimabDrug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A: Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1Time frame: Week 16
  2. Part B: Percentage of Participants who Achieve Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI-70) Response, Defined as ≥ 70% Decrease in CLASI-A Score From BaselineTime frame: Baseline to Week 24

Locations

315 sites in 30 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • UAB Center for Women's Reproductive Health

    Birmingham, Alabama

  • Arizona Arthritis & Rheumatology Research, PLLC

    Phoenix, Arizona

  • The Regents of the University of California

    La Jolla, California

  • Dermatology Research Associates

    Los Angeles, California

  • Clinical Science Institute

    Santa Monica, California

  • Inland Rheumatology Clinical Trials, Inc.

    Upland, California

  • Denver Arthritis Clinic

    Denver, Colorado

  • Omega Research Debary, LLC

    DeBary, Florida

  • Centre for Rheumatology, Immunology and Arthritis

    Fort Lauderdale, Florida

  • University of Florida

    Gainesville, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Millennium Medical Research, LLC

    Miami, Florida

  • Medical Research Center of Miami

    Miami, Florida

  • Diverse Clinical Research LLC

    Miami, Florida

  • Charisma Medical and Research Center

    Miami Lakes, Florida

  • Leading Edge Dermatology

    Plantation, Florida

  • Augusta University

    Augusta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • OrthoIllinois

    Rockford, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Equity Medical

    Bowling Green, Kentucky

  • LSU Health Sciences Center Shreveport

    New Orleans, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Brigham And Women's Hospital

    Boston, Massachusetts

  • Essential Dermatology

    Natick, Massachusetts

  • Beacon Clinical Research, LLC

    Quincy, Massachusetts

  • University of Massachusetts, Worcester

    Worcester, Massachusetts

  • David Fivenson, MD, Dermatology, PLLC

    Ann Arbor, Michigan

  • Oakland Hills Dermatology

    Auburn Hills, Michigan

  • AA MRC LLC Ahmed Arif Medical Research Center

    Flint, Michigan

  • Revival Research Institute, LLC

    Troy, Michigan

  • Saint Louis University

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Albuquerque Center For Rheumatology

    Albuquerque, New Mexico

  • University of New Mexico School of Medicine

    Albuquerque, New Mexico

  • NYU Langone Brooklyn

    Brooklyn, New York

  • Universal Dermatology, PLLC

    Fairport, New York

  • Northwell Health, Inc. PRIME

    Great Neck, New York

  • Columbia University Medical center

    New York, New York

Showing 40 of 315 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.